Align TechnologyALGN
About: Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
Employees: 20,945
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
1.02% more ownership
Funds ownership: 86.48% [Q3] → 87.5% (+1.02%) [Q4]
0% more first-time investments, than exits
New positions opened: 107 | Existing positions closed: 107
2% less funds holding
Funds holding: 716 [Q3] → 702 (-14) [Q4]
17% less capital invested
Capital invested by funds: $16.4B [Q3] → $13.6B (-$2.78B) [Q4]
22% less repeat investments, than reductions
Existing positions increased: 211 | Existing positions reduced: 271
43% less funds holding in top 10
Funds holding in top 10: 7 [Q3] → 4 (-3) [Q4]
48% less call options, than puts
Call options by funds: $163M | Put options by funds: $313M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Mizuho Steven Valiquette 29% 1-year accuracy 2 / 7 met price target | 41%upside $250 | Outperform Maintained | 25 Mar 2025 |
Piper Sandler Jason Bednar 18% 1-year accuracy 7 / 38 met price target | 33%upside $235 | Overweight Reiterated | 18 Mar 2025 |
Wells Fargo Vik Chopra 27% 1-year accuracy 3 / 11 met price target | 44%upside $255 | Overweight Initiated | 14 Feb 2025 |
Evercore ISI Group Elizabeth Anderson 42% 1-year accuracy 14 / 33 met price target | 47%upside $260 | Outperform Maintained | 6 Feb 2025 |
Morgan Stanley Erin Wright 44% 1-year accuracy 11 / 25 met price target | 53%upside $272 | Overweight Maintained | 6 Feb 2025 |
Financial journalist opinion
Based on 11 articles about ALGN published over the past 30 days
